(S1 (S (NP (NP (JJ Molecular) (NN characterization)) (PP (IN of) (NP (NP (JJ angiogenic) (NNS properties)) (PP (IN of) (NP (JJ human) (JJ oral) (JJ squamous) (NN cell) (NN carcinoma) (NNS cells))))) (. .))))
(S1 (S (S (NP (JJ Little)) (VP (VBZ is) (VP (VBN known) (PP (IN about) (NP (NP (NP (DT the) (NN specificity)) (PP (IN of) (NP (NP (JJ angiogenic) (NNS properties)) (PP (IN of) (NP (JJ oral) (NN cancer) (NNS cells)))))) (CC and) (NP (DT the) (JJ possible) (NNS mechanisms))))))) (. .)))
(S1 (S (S (NP (NP (JJ Stimulatory) (NNS effects)) (PP (IN on) (NP (NP (NP (NN proliferation)) (CC and) (NP (NN migration))) (PP (IN of) (NP (NP (JJ human) (JJ umbilical) (NN vein) (JJ endothelial) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NN HUVEC)) (-RRB- -RRB-))))))) (VP (VBD characterized) (NP (NP (DT the) (JJ angiogenic) (NNS properties)) (PP (IN of) (NP (NP (JJ oral) (NN cancer) (NNS cells)) (CONJP (CC but) (RB not)) (NP (NP (JJ normal) (JJ oral) (NNS keratinocytes)) (PRN (-LRB- -LRB-) (NP (NN NOK)) (-RRB- -RRB-)))))))) (. .)))
(S1 (S (S (NP (NN ELISA)) (VP (VBD found) (NP (NP (DT the) (NN presence)) (PP (PP (IN of) (NP (NP (JJ vascular) (JJ endothelial) (NN growth) (NNS factors)) (PRN (-LRB- -LRB-) (NP (NN VEGF)) (-RRB- -RRB-)))) (CC both) (PP (IN in) (NP (NP (DT the) (VBN tested) (JJ oral) (NN cancer) (NNS cells)) (CC and) (NP (NN NOK)))))))) (. .)))
(S1 (S (S (NP (NP (NN Attenuation)) (PP (IN of) (NP (DT the) (JJ proangiogenic) (NNS effects))) (PP (IN by) (NP (NN neutralizing) (NN VEGF) (NNS antibodies)))) (VP (VBZ suggests) (S (NP (NN VEGF)) (VP (VBP play) (NP (DT a) (JJ key) (NN role)) (PP (IN in) (NP (NP (DT the) (NN acquisition)) (PP (IN of) (NP (DT the) (JJ angiogenic) (NN phenotype))) (PP (IN in) (NP (JJ oral) (NN cancer) (NNS cells))))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN Western) (NN blotting)) (PP (IN of) (NP (NN p53)))) (CC and) (NP (NP (NN murine) (JJ double) (NN mutant) (CD 2)) (PRN (-LRB- -LRB-) (NP (NN Mdm2)) (-RRB- -RRB-))) (CONJP (RB together) (IN with)) (NP (NN p53) (NN DNA) (NN sequencing) (NN analysis))) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (NN p53) (NN function) (NN loss)) (PP (IN by) (NP (NP (NN mutation)) (CC or) (NP (NP (NN overexpression)) (PP (IN of) (NP (NN Mdm2))))))) (VP (VBD occurred) (PP (IN in) (NP (DT all) (VBN tested) (JJ oral) (NN cancer) (NNS cells))) (ADVP (RB regardless) (PP (IN of) (NP (PRP$ their) (NN etiology))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN summary))) (, ,) (NP (NP (DT the) (JJ angiogenic) (NN property)) (PP (IN of) (NP (JJ oral) (NN cancer) (NNS cells)))) (VP (VBZ is) (VP (VBN mediated) (PP (IN by) (NP (NP (NP (JJ many) (NNS factors)) (PP (IN in) (NP (NP (NN addition)) (PP (TO to) (NP (NN VEGF)))))) (CC and) (NP (NP (DT the) (JJ functional) (NN status)) (PP (IN of) (NP (NN p53))))))))) (. .)))
